Van't Wout J W, Mattie H, van Furth R
Department of Infectious Diseases, University Hospital, Leiden, The Netherlands.
J Antimicrob Chemother. 1988 May;21(5):665-72. doi: 10.1093/jac/21.5.665.
Fluconazole (UK-49,858) is a new bis-triazole antifungal drug that can be administered both orally and intravenously. We conducted an open clinical trial on the efficacy of fluconazole (50-100 mg) once daily in 20 non-neutropenic patients with deep-seated fungal infections. Seventeen patients (eight females, nine males, median age 56 years) could be evaluated clinically. All patients had an underlying disease, while eight also received immunosuppressive therapy. The median duration of treatment was 33 days (range 8-194 days). Clinical cure or improvement was achieved in 14 of 17 patients (82%). Nine patients were both clinically and microbiologically cured. Fluconazole was especially effective in patients with candidal infections. Two patients with cryptococcal meningitis were clinically cured; one of the two was also microbiologically cured. No serious side effects of fluconazole were encountered.
氟康唑（UK - 49,858）是一种新型的双三唑类抗真菌药物，可口服给药，也可静脉给药。我们对20例非中性粒细胞减少的深部真菌感染患者进行了一项开放临床试验，观察每日一次服用氟康唑（50 - 100毫克）的疗效。17例患者（8名女性，9名男性，中位年龄56岁）可进行临床评估。所有患者均有基础疾病，其中8例还接受了免疫抑制治疗。治疗的中位持续时间为33天（范围8 - 194天）。17例患者中有14例（82%）实现了临床治愈或病情改善。9例患者临床和微生物学均治愈。氟康唑对念珠菌感染患者尤其有效。2例隐球菌性脑膜炎患者临床治愈；其中1例微生物学也治愈。未发现氟康唑有严重副作用。
